Said Jonathan, Pinter-Brown Lauren
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Clin Adv Hematol Oncol. 2009 Nov;7(11):S1, S4-13; quiz S15.
The diverse group of peripheral T-cell lymphomas (PTCLs) present clinical and pathologic challenges. Proper recognition and diagnosis can be difficult even for experienced pathologists because these entities tend to vary in morphologic appearance from case to case within the same subtype and often mimic other diseases in appearance. This makes the use of immunologic markers an essential tool. Clinically, PTCLs are difficult to treat because they often present in an advanced stage and are resistant to traditional first-line chemotherapeutic regimens. Five-year overall survival rates are dismal, ranging from 20-50%, depending upon subtype. Although high-dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation has been reported to improve overall survival in patients with PTCL, this therapy is only feasible for the small minority of patients who experience a durable complete response to induction therapy. Therefore, there is much interest in the field in developing novel first-line approaches that will improve response rates and duration. In this monograph, 2 case studies of different subtypes of PTCL will be presented, and the clinical and pathologic features will be discussed. In addition, data on emerging therapies for PTCLs will be reviewed with an emphasis on novel and investigational agents.
外周T细胞淋巴瘤(PTCL)种类多样,在临床和病理方面都具有挑战性。即便对于经验丰富的病理学家而言,准确识别和诊断也可能存在困难,因为这些淋巴瘤在同一亚型内,不同病例的形态学表现往往各异,且外观上常与其他疾病相似。这使得免疫标记物的应用成为一项重要工具。在临床上,PTCL难以治疗,因为它们通常在晚期出现,并且对传统的一线化疗方案具有抗性。五年总生存率很低,根据亚型不同,在20%至50%之间。尽管有报道称,高剂量序贯化疗后进行自体造血干细胞移植可提高PTCL患者的总生存率,但这种治疗仅适用于少数对诱导治疗产生持久完全缓解的患者。因此,该领域对开发能提高缓解率和缓解持续时间的新型一线治疗方法有着浓厚兴趣。在本专著中,将展示2例不同亚型PTCL的病例研究,并讨论其临床和病理特征。此外,还将回顾PTCL新兴治疗方法的数据,重点关注新型和研究性药物。